Update shared on23 Aug 2025
Fair value Increased 10%Driven by improvements in net profit margin and revenue growth forecasts, analysts have raised their fair value estimate for Xeris Biopharma Holdings from $8.17 to $9.00.
What's in the News
- Xeris Biopharma Holdings raised full-year 2025 revenue guidance to $280–$290 million, up from the prior range of $260–$275 million.
- The company previously reaffirmed 2025 total revenue guidance of $260–$275 million.
Valuation Changes
Summary of Valuation Changes for Xeris Biopharma Holdings
- The Consensus Analyst Price Target has significantly risen from $8.17 to $9.00.
- The Net Profit Margin for Xeris Biopharma Holdings has risen from 18.01% to 19.23%.
- The Consensus Revenue Growth forecasts for Xeris Biopharma Holdings has risen from 20.4% per annum to 21.5% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.